Abstract
The first study to visually document the efficacy of ‘Neoral’, Novartis’ microemulsion formulation of cyclosporin, in severe, recalcitrant plaque psoriasis has shown that the drug effectively relieves signs and symptoms of this disease such as pain, itching, scaling and irritation. Several studies have shown that cyclosporin is useful in this condition, as evidenced by improvements in Psoriasis Area and Severity Index (PASI) scores, but until now none of the studies had actually visually documented improvements in skin. Results from the study were released at the 57th Annual Meeting of the American Academy of Dermatology [New Orleans, US; March 1999].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
